| Jammy J Dinnel, CRNA | |
|
4309 W Medical Center Dr Ste A201, Mchenry, IL 60050-8411 | |
| (815) 385-0084 | |
| (815) 385-8968 |
| Full Name | Jammy J Dinnel |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 27 Years |
| Location | 4309 W Medical Center Dr Ste A201, Mchenry, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457439465 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 209-004448 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Javon Bea Hospital | Rockford, IL | Hospital |
| Entity Name | Rockford Health Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043242886 PECOS PAC ID: 2567374036 Enrollment ID: O20031103000584 |
News Archive
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire an 80% stake in Xiangao Investment Company Ltd, an investment company registered in China, as its sole business, holds a 49% stake in Jilin Boda Pharmaceutical Co. Ltd..
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
The brain is a complex organ full of neurons that work together to help us move, feel, think, and more. A multidisciplinary group from the University of Pittsburgh and Carnegie Mellon University is working to expand the amount of information researchers can receive from a neural interface device and received two grants from the National Science Foundation for their collaborative effort.
K7 LLC's K7C Cervical Spacer, a spinal implant device using Evonik's VESTAKEEP PEEK (polyetheretherketone), has received the U.S. Food and Drug Administration's (FDA) 510(k) approval for use as an Intervertebral Body Fusion (IBF) device.
Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Today, Shire plc, the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.
› Verified 6 days ago
| Entity Name | Windy City Anesthesia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932248622 PECOS PAC ID: 9234033572 Enrollment ID: O20031120000022 |
News Archive
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire an 80% stake in Xiangao Investment Company Ltd, an investment company registered in China, as its sole business, holds a 49% stake in Jilin Boda Pharmaceutical Co. Ltd..
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
The brain is a complex organ full of neurons that work together to help us move, feel, think, and more. A multidisciplinary group from the University of Pittsburgh and Carnegie Mellon University is working to expand the amount of information researchers can receive from a neural interface device and received two grants from the National Science Foundation for their collaborative effort.
K7 LLC's K7C Cervical Spacer, a spinal implant device using Evonik's VESTAKEEP PEEK (polyetheretherketone), has received the U.S. Food and Drug Administration's (FDA) 510(k) approval for use as an Intervertebral Body Fusion (IBF) device.
Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Today, Shire plc, the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.
› Verified 6 days ago
| Entity Name | Aspen Anesthesia, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225044043 PECOS PAC ID: 6800898347 Enrollment ID: O20070212000653 |
News Archive
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire an 80% stake in Xiangao Investment Company Ltd, an investment company registered in China, as its sole business, holds a 49% stake in Jilin Boda Pharmaceutical Co. Ltd..
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
The brain is a complex organ full of neurons that work together to help us move, feel, think, and more. A multidisciplinary group from the University of Pittsburgh and Carnegie Mellon University is working to expand the amount of information researchers can receive from a neural interface device and received two grants from the National Science Foundation for their collaborative effort.
K7 LLC's K7C Cervical Spacer, a spinal implant device using Evonik's VESTAKEEP PEEK (polyetheretherketone), has received the U.S. Food and Drug Administration's (FDA) 510(k) approval for use as an Intervertebral Body Fusion (IBF) device.
Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Today, Shire plc, the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.
› Verified 6 days ago
| Entity Name | Huntley Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205282019 PECOS PAC ID: 0143515825 Enrollment ID: O20160819000149 |
News Archive
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire an 80% stake in Xiangao Investment Company Ltd, an investment company registered in China, as its sole business, holds a 49% stake in Jilin Boda Pharmaceutical Co. Ltd..
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
The brain is a complex organ full of neurons that work together to help us move, feel, think, and more. A multidisciplinary group from the University of Pittsburgh and Carnegie Mellon University is working to expand the amount of information researchers can receive from a neural interface device and received two grants from the National Science Foundation for their collaborative effort.
K7 LLC's K7C Cervical Spacer, a spinal implant device using Evonik's VESTAKEEP PEEK (polyetheretherketone), has received the U.S. Food and Drug Administration's (FDA) 510(k) approval for use as an Intervertebral Body Fusion (IBF) device.
Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Today, Shire plc, the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.
› Verified 6 days ago
| Entity Name | Moline Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134683758 PECOS PAC ID: 4284976374 Enrollment ID: O20190419000025 |
News Archive
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire an 80% stake in Xiangao Investment Company Ltd, an investment company registered in China, as its sole business, holds a 49% stake in Jilin Boda Pharmaceutical Co. Ltd..
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
The brain is a complex organ full of neurons that work together to help us move, feel, think, and more. A multidisciplinary group from the University of Pittsburgh and Carnegie Mellon University is working to expand the amount of information researchers can receive from a neural interface device and received two grants from the National Science Foundation for their collaborative effort.
K7 LLC's K7C Cervical Spacer, a spinal implant device using Evonik's VESTAKEEP PEEK (polyetheretherketone), has received the U.S. Food and Drug Administration's (FDA) 510(k) approval for use as an Intervertebral Body Fusion (IBF) device.
Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Today, Shire plc, the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.
› Verified 6 days ago
| Entity Name | Gip Anesthesia Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821733726 PECOS PAC ID: 4688043177 Enrollment ID: O20230113001346 |
News Archive
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire an 80% stake in Xiangao Investment Company Ltd, an investment company registered in China, as its sole business, holds a 49% stake in Jilin Boda Pharmaceutical Co. Ltd..
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
The brain is a complex organ full of neurons that work together to help us move, feel, think, and more. A multidisciplinary group from the University of Pittsburgh and Carnegie Mellon University is working to expand the amount of information researchers can receive from a neural interface device and received two grants from the National Science Foundation for their collaborative effort.
K7 LLC's K7C Cervical Spacer, a spinal implant device using Evonik's VESTAKEEP PEEK (polyetheretherketone), has received the U.S. Food and Drug Administration's (FDA) 510(k) approval for use as an Intervertebral Body Fusion (IBF) device.
Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Today, Shire plc, the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jammy J Dinnel, CRNA 4309 W Medical Center Dr Ste A201, Mchenry, IL 60050-8411 Ph: (815) 385-0084 | Jammy J Dinnel, CRNA 4309 W Medical Center Dr Ste A201, Mchenry, IL 60050-8411 Ph: (815) 385-0084 |
News Archive
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire an 80% stake in Xiangao Investment Company Ltd, an investment company registered in China, as its sole business, holds a 49% stake in Jilin Boda Pharmaceutical Co. Ltd..
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
The brain is a complex organ full of neurons that work together to help us move, feel, think, and more. A multidisciplinary group from the University of Pittsburgh and Carnegie Mellon University is working to expand the amount of information researchers can receive from a neural interface device and received two grants from the National Science Foundation for their collaborative effort.
K7 LLC's K7C Cervical Spacer, a spinal implant device using Evonik's VESTAKEEP PEEK (polyetheretherketone), has received the U.S. Food and Drug Administration's (FDA) 510(k) approval for use as an Intervertebral Body Fusion (IBF) device.
Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Today, Shire plc, the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.
› Verified 6 days ago
Ms. Margaret Mary Dosemagen, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 4309 W Medical Center Dr, Suite A201, Mchenry, IL 60050 Phone: 815-385-0084 Fax: 815-385-8968 | |
Mr. Gregory Francis Zankle, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4309 W Medical Center Dr, Suite A201, Mchenry, IL 60050 Phone: 815-385-0084 Fax: 815-385-8968 | |
Haile E Fitzgerald, DNP, CRNA, APRN Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4201 W Medical Center Dr, Mchenry, IL 60050 Phone: 815-759-4178 | |
Mr. Dennis Jasieniecki, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 4309 W Medical Center Dr Ste A201, Mchenry, IL 60050 Phone: 815-385-0084 Fax: 815-385-8968 | |
Miss Ellen B Steckbar, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4309 W Medical Center Dr, Suite A201, Mchenry, IL 60050 Phone: 815-385-0084 Fax: 815-385-8968 | |
Ms. Karen S. Filipowski, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 4309 W Medical Center Dr, Suite A201, Mchenry, IL 60050 Phone: 815-385-0084 Fax: 815-385-8968 |